Glaukos (NYSE:GKOS) Stock Rating Upgraded by StockNews.com

Glaukos (NYSE:GKOS – Get Free Report) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Friday.

A number of other research analysts also recently issued reports on GKOS. Mizuho raised their price target on Glaukos from $48.00 to $52.00 in a research note on Tuesday, April 18th. 888 reaffirmed a “maintains” rating on shares of Glaukos in a report on Thursday, May 4th. TheStreet upgraded shares of Glaukos from a “d+” rating to a “c-” rating in a research note on Thursday, June 1st. Citigroup lifted their price objective on shares of Glaukos from $59.00 to $85.00 in a research note on Monday. Finally, BTIG Research increased their target price on shares of Glaukos from $58.00 to $67.00 in a research note on Monday, June 5th. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $66.44.

Get Glaukos alerts:

Glaukos Stock Performance

Shares of GKOS opened at $71.63 on Friday. The company has a quick ratio of 6.02, a current ratio of 6.67 and a debt-to-equity ratio of 0.70. Glaukos has a 52-week low of $40.45 and a 52-week high of $73.38. The stock has a 50 day moving average price of $64.02 and a 200 day moving average price of $53.68. The company has a market capitalization of $3.45 billion, a price-to-earnings ratio of -24.53 and a beta of 1.28.

Glaukos (NYSE:GKOS – Get Free Report) last posted its earnings results on Wednesday, May 3rd. The medical instruments supplier reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.02. Glaukos had a negative net margin of 48.15% and a negative return on equity of 21.20%. The firm had revenue of $73.90 million for the quarter, compared to the consensus estimate of $67.74 million. During the same period last year, the firm posted ($0.38) EPS. The company’s revenue was up 9.2% on a year-over-year basis. Research analysts predict that Glaukos will post -2.27 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Thomas William Burns sold 3,704 shares of the stock in a transaction dated Tuesday, May 16th. The shares were sold at an average price of $60.01, for a total value of $222,277.04. Following the completion of the transaction, the chief executive officer now owns 673,963 shares in the company, valued at approximately $40,444,519.63. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders have sold 104,707 shares of company stock worth $7,131,641. Corporate insiders own 7.80% of the company’s stock.

Hedge Funds Weigh In On Glaukos

Several hedge funds have recently bought and sold shares of GKOS. Amalgamated Bank grew its holdings in Glaukos by 0.9% in the fourth quarter. Amalgamated Bank now owns 23,073 shares of the medical instruments supplier’s stock valued at $1,008,000 after purchasing an additional 204 shares during the last quarter. American Century Companies Inc. grew its stake in Glaukos by 3.1% in the 1st quarter. American Century Companies Inc. now owns 6,878 shares of the medical instruments supplier’s stock valued at $339,000 after acquiring an additional 207 shares during the last quarter. State of Alaska Department of Revenue increased its holdings in Glaukos by 0.7% during the 4th quarter. State of Alaska Department of Revenue now owns 33,217 shares of the medical instruments supplier’s stock valued at $1,450,000 after acquiring an additional 246 shares in the last quarter. Captrust Financial Advisors increased its holdings in Glaukos by 17.1% during the 2nd quarter. Captrust Financial Advisors now owns 1,738 shares of the medical instruments supplier’s stock valued at $79,000 after acquiring an additional 254 shares in the last quarter. Finally, UBS Asset Management Americas Inc. raised its position in Glaukos by 0.5% during the second quarter. UBS Asset Management Americas Inc. now owns 61,400 shares of the medical instruments supplier’s stock worth $2,789,000 after acquiring an additional 299 shares during the last quarter. 97.50% of the stock is owned by hedge funds and other institutional investors.

About Glaukos

(Get Free Report)

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

Featured Stories

• Five stocks we like better than Glaukos
• Delta Takes Flight: Double-Digit Upside In Sight
• Generac Powers Up as Summer Temperatures Rise
• 3 Reasons Why Rivian Can Continue To Surge Higher
• Despite Breaking Higher, Analysts Remain Cautious HP Inc.
• PepsiCo Can Soar To New Highs In The 2nd Half

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.